Immunization against bovine herpesvirus-1 infection. Preliminary tests in calves with a DNA vaccine

Castrucci, G; Ferrari, M; Marchini, Cristina; Salvatori, Daniela; Provinciali, Mauro; Tosini, A.; Petrini, Stefano; Sardonini, Q; Dico, M Lo; Frigeri, F; Amici, Augusto

doi:10.1016/j.cimid.2003.09.001

Cited by 15 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The plates were held at room temperature (22°C) for 90 min, then 20,000 MDBK cells were added to each well. Neutralization titers were expressed as log 2 of the highest dilution inhibiting cytopathology (Castrucci et al 2004). …”

Section: Serological Analysismentioning

confidence: 99%

Survey of Neospora caninum and bovine herpes virus 1 coinfection in cattle

et al. 2006

View full text Add to dashboard Cite

A seroprevalence survey of Neospora caninum and bovine herpesvirus 1 (BHV-1) was conducted in cattle pasturing in an area of the southern Italian Apennines to investigate the coinfection of these two pathogens. Blood samples were collected from 948 pastured cattle raised on 81 farms. Sera were tested for antibodies to N. caninum and to BHV-1 using an ELISA assay and a neutralization test, respectively. Out of the 81 farms sampled, 63 (77.8%) were positive for N. caninum and 80 (98.8%) for BHV-1. Coinfection was found in 62 (76.5%) farms. Out of the 948 bovine sera samples, 303 (32.0%) had antibodies to N. caninum and 735 (77.5%) to BHV-1. The copresence of antibodies to N. caninum and BHV-1 was found in 256 (27.0%) cattle. The logistic regression results indicated that seropositivity for BHV-1 was a risk factor for N. caninum seropositivity and seropositivity for N. caninum was a risk factor for BHV-1 seropositivity.

show abstract

Section: Serological Analysismentioning

confidence: 99%

Survey of Neospora caninum and bovine herpes virus 1 coinfection in cattle

et al. 2006

View full text Add to dashboard Cite

show abstract

“…This has the benefit of intracellular expression of the antigen, which may be targeted to the class I MHC for efficient induction of cellular immune responses (30, 31). Viral surface glycoproteins gB, gC, and gD of BoHV-1 have been selected as candidate antigens in DNA immunization (32, 33). Glicoprotein D, in particular, has shown promising results in mice (34) and partial success in calves (17, 32, 33).…”

Section: Introductionmentioning

confidence: 99%

“…Viral surface glycoproteins gB, gC, and gD of BoHV-1 have been selected as candidate antigens in DNA immunization (32, 33). Glicoprotein D, in particular, has shown promising results in mice (34) and partial success in calves (17, 32, 33). But, since the potency of naked DNA vaccines is limited by their inability to amplify and spread in vivo , adjuvant incorporation could be a good option to increase the magnitude and direction of the immune response.…”

Section: Introductionmentioning

confidence: 99%

A DNA Vaccine Formulated with Chemical Adjuvant Provides Partial Protection against Bovine Herpes Virus Infection in Cattle

Quattrocchi¹,

Soria

Langellotti

et al. 2017

Front. Immunol.

View full text Add to dashboard Cite

Bovine herpesvirus-1 (BoHV-1) is the causative agent of bovine infectious rhinotracheitis, an important disease worldwide. Although conventional BoHV-1 vaccines, including those based on the use of modified live virus and also inactivated vaccines, are currently used in many countries, they have several disadvantages. DNA vaccines have emerged as an attractive approach since they have the potential to induce both humoral and cellular immune response; nevertheless, it is largely known that potency of naked DNA vaccines is limited. We demonstrated previously, in the murine model, that the use of adjuvants in combination with a DNA vaccine against BoHV-1 is immunologically beneficial. In this study, we evaluate the immune response and protection against challenge elicited in bovines, by a DNA vaccine carrying the sequence of secreted version of glycoprotein D (gD) of BoHV-1 formulated with chemical adjuvants. Bovines were vaccinated with formulations containing the sequence of gD alone or in combination with adjuvants ESSAI 903110 or Montanide™ 1113101PR. After prime vaccination and two boosters, animals were challenged with infectious BoHV-1. Formulations containing adjuvants Montanide™ 1113101PR and ESSAI 903110 were both, capable of increasing humoral immune response against the virus and diminishing clinical symptoms. Nevertheless, only formulations containing adjuvant Montanide™ 1113101PR was capable of improving cellular immune response and diminishing viral excretion. To our knowledge, it is the first time that a BoHV-1 DNA vaccine is combined with adjuvants and tested in cattle. These results could be useful to design a vaccine for the control of bovine rhinotracheitis.

show abstract

“…When virus reactivation was observed, the isolates were subjected to a number of tests to determine whether the reactivated vaccine viruses had modified their properties when compared with the original vaccines (Castrucci et al, 2002a,b). The second part of the project concerns the study of the experimental DNA vaccine (Castrucci et al, 2004). Plasmid pcDNA3.1.-tgD was constructed by cloning the BHV-1 gene encoding a truncated form of gD (tgD) into pc DNA3.1.…”

Section: Methodsmentioning

confidence: 99%